United States Gene Panel Market expected to grow at a CAGR of 19.6% during 2024-2031 | Major Compnies 2026 - Thermo Fisher Scientific, Agilent Technologies, QIAGEN

Leander, Texas and Tokyo, Japan - Jan.09.2026
As per DataM intelligence research report" Gene Panel market to grow at a CAGR of 19.6% during the forecast period 2024 - 2031." Cost-effective genetic testing and personalized medicine are boosting gene panel usage.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/gene-panel-market?prasad

United States Recent Industry Developments

✅ In November 2025, Illumina launched a new "Comprehensive Genomic Profiling" (CGP) kit The pan-cancer panel covers over 500 genes to identify rare driver mutations It supports the adoption of precision oncology in community U.S. cancer centers

✅ In October 2025, Invitae released an expanded carrier screening panel for reproductive health The panel includes new genes relevant to diverse ethnic populations It promotes health equity in U.S. prenatal care

✅ In September 2025, Thermo Fisher Scientific introduced a rapid gene panel for myeloid malignancies The NGS assay delivers results in under 24 hours It enables faster treatment initiation for U.S. leukemia patients

✅ In August 2025, The FDA approved a companion diagnostic gene panel for a new targeted therapy The approval links specific genetic variants to drug eligibility It cements the role of gene panels in U.S. standard of care

Japan Recent Industry Developments

✅ In December 2025, Sysmex Corporation launched a gene panel specifically for Japanese hereditary cancers The panel includes variants more common in the East Asian population It improves the diagnostic yield for Japanese patients

✅ In November 2025, The National Cancer Center Japan expanded its "LC-SCRUM" screening panel The project now covers rare cancers to match patients with clinical trials It accelerates drug development for unmet needs in Japan

✅ In October 2025, Konica Minolta (REALM IDx) partnered with Japanese hospitals to standardize panel reporting The initiative creates a unified format for genomic reports It facilitates data sharing and second opinions in Japan's healthcare system

✅ In September 2025, Canon Medical Systems acquired a bioinformatics firm to enhance its gene panel analysis The acquisition adds AI interpretation to their sequencing hardware It offers an end-to-end genomic solution for Japanese labs

Gene Panel Market: Drivers
The gene panel market is expanding due to rising demand for genetic testing. Advances in sequencing technologies reduce costs. Growing use in oncology and rare disease diagnosis drives adoption. Expansion of personalized medicine supports growth. Regulatory approvals enhance clinical confidence. Increasing healthcare investments strengthen demand.

Market growth is reinforced by integration with digital diagnostics. Emerging markets adopt genetic testing. Partnerships between labs and biotech firms accelerate innovation. Improved turnaround times boost adoption. Focus on preventive care supports growth. Gene panels enable targeted diagnostics.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/gene-panel-market?prasad

Gene Panel Market: Major Players
Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI (China), Eurofins Scientific, Novogene Corporation (China), F. Hoffmann-La Roche AG, Integrated DNA Technologies, Genewiz Inc and Illumina Inc.

Segment Covered in the Gene Panel Market:
By Product & Service
The market is segmented into test kits 55% and testing services 45%, with test kits dominating due to their widespread adoption in hospitals and diagnostic laboratories for in-house testing. Test kits offer faster turnaround times, standardization, and cost efficiency. Testing services are growing rapidly as smaller labs and clinics outsource complex genomic testing to specialized service providers.

By Technique
Techniques include amplicon-based approaches 60% and hybridization-based approaches 40%. Amplicon-based methods dominate due to high sensitivity, low DNA input requirements, and faster sequencing workflows, particularly in oncology applications. Hybridization-based approaches are preferred for broader genomic coverage and complex variant detection, supporting advanced research and comprehensive diagnostic panels.

By Design
By design, the market comprises predesigned gene panels 65% and customized gene panels 35%. Predesigned panels dominate owing to regulatory approvals, clinical validation, and ease of adoption in routine diagnostics. Customized panels are gaining traction in research, rare disease diagnostics, and precision medicine applications where tailored gene selection is required.

By Application
Applications include cancer risk assessment 40%, diagnosis of congenital diseases 25%, pharmacogenetics 20%, and other applications 15%. Cancer risk assessment leads due to the growing burden of oncology cases and increasing use of NGS-based gene panels for early detection and treatment planning. Pharmacogenetics is expanding as precision medicine adoption increases.

By End-User
End-users include hospitals and diagnostic laboratories 45%, research and academic institutes 30%, and pharmaceutical and biotechnology companies 25%. Hospitals and diagnostic labs dominate driven by rising demand for genetic testing in clinical diagnostics. Research institutes and pharma & biotech companies increasingly use gene panels for biomarker discovery, drug development, and clinical trials.

Regional Analysis
North America - 40% Share
North America leads with a 40% share due to advanced genomic infrastructure, high adoption of precision medicine, strong reimbursement frameworks, and the presence of major NGS and diagnostics companies in the U.S. and Canada.

Europe - 25% Share
Europe accounts for 25% share supported by growing government-funded genomics programs, rising cancer screening initiatives, and expanding diagnostic capabilities in Germany, the U.K., France, and Italy.

Asia Pacific - 20% Share
Asia Pacific holds 20% share driven by increasing healthcare expenditure, expanding genomic research, and rising adoption of genetic testing in China, Japan, South Korea, and India.

Latin America - 8% Share
Latin America represents 8% share with growing awareness of genetic testing, improving diagnostic infrastructure, and increasing adoption in Brazil and Mexico.

Middle East & Africa - 7% Share
Middle East & Africa accounts for 7% share, supported by investments in advanced healthcare diagnostics, growing focus on rare disease screening, and expanding genomics initiatives in the UAE, Saudi Arabia, and South Africa.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=gene-panel-market

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.